Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 79,372 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Ankle Fractures
Interventions: Fibular intramedullary nail, Open reduction and internal fixation; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma
Interventions: Tesetaxel; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel, 5-hydroxytryptamine subtype 3 receptor antagonist, Neurokinin-1 receptor antagonist, Corticosteroid; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Lexington, Kentucky • Baltimore, Maryland • Pittsburgh, Pennsylvania + 1 more

Conditions: Prostatic Neoplasms
Interventions: PF-06755992, PF-06755990, TDS-IM Electroporation Device, Tremelimumab, PF-06801591, PF-06753512; Biological · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 19
States / cities: Tucson, Arizona • New Haven, Connecticut • Bethesda, Maryland + 10 more

Conditions: Urinary Tract Infections
Interventions: Computer-assisted treatment group, Usual care group; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Fresno, California • Oakland, California • San Francisco, California

Conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple Myeloma
Interventions: pomalidomide, marizomib, low-dose dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Multiple Myeloma
Interventions: Ganetespib, Bortezomib, Dexamethasone; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Denver, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more

Conditions: Obesity, Overweight
Interventions: AC2307, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 15 more

Conditions: Headache, Tension-Type
Interventions: Experimental paracetamol, Paracetamol marketed formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Interventions: CTX-471, Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more

Conditions: Prostate CA
Interventions: Dexamethasone, TAP block; Drug · Procedure
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1 Infection
Interventions: Islatravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Hollywood, Florida • Salt Lake City, Utah

Conditions: Mesothelioma
Interventions: Carboplatin, Bevacizumab and Pemetrexed; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Health Behavior
Interventions: Stress Management Control, Adapted MBC2 Program; Behavioral
Lead sponsor: Nancy Schoenberg; Other
Eligibility: 18 Years to 100 Years
Enrollment: 279 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Benham, Kentucky

Conditions: Healthy Volunteers
Interventions: Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl); Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Head and Neck Cancer
Interventions: MEHD7945A, cetuximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Stanford, California • Aurora, Colorado • Miami, Florida + 10 more

Conditions: Visual Field Defect, Peripheral, Glaucoma, Open-Angle
Interventions: Vitamin B3, Pyruvate, Placebo; Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Dental Implantation, Missing Teeth, Periodontitis, Adult, Mucositis
Interventions: Enamel Matrix Derivative; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 18 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Overweight, Obesity
Interventions: CCTP, Nutritional counseling; Behavioral
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 25 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Food Effect
Interventions: VS-6766; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Persistent Pulmonary Hypertension of the Newborn
Interventions: IV Remodulin, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 1 Hour to 14 Days
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 14
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Cardiovascular Health
Interventions: Singing with Music Therapist, Singing with Guided Video, Control Arm; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 55 Years to 79 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Barrett's Esophagus With Dysplasia
Interventions: Mucosal Impedance, Research Biopsies, Volumetric Laser Endomicroscopy; Device · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Rochester, Minnesota • New York, New York

Conditions: Prostate Cancer
Interventions: estramustine phosphate sodium, ixabepilone; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Search by objective public record fields.

Diabetic Fibular Nail Study

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects

A Pharmacokinetic Study of an Experimental Paracetamol Formulation

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Evaluation of Addition of Dexamethasone to Transversus Abdominis Plane (TAP) Peripheral Nerve Block

Islatravir and Methadone Pharmacokinetics (MK-8591-029)

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

Make Better Choices 2 for Rural Appalachians

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin)

The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness

Evaluating the Impact of a Culinary Coaching Tele-medicine Program

Food Effect of VS-6766 in Healthy Adult Subjects

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Singing and Cardiovascular Health in Older Adults

Characterization of the Neo-squamous Epithelial Barrier

Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer